Evolus (EOLS) Expected to Announce Earnings on Monday

Evolus (NASDAQ:EOLS) is expected to post its Q1 2026 results after the market closes on Monday, May 4th. Analysts expect Evolus to post earnings of ($0.14) per share and revenue of $72.5210 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 4, 2026 at 4:30 PM ET.

Evolus (NASDAQ:EOLS) last announced its earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The company had revenue of $90.30 million for the quarter, compared to analysts’ expectations of $89.58 million. On average, analysts expect Evolus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolus Price Performance

EOLS opened at $5.33 on Friday. The business’s 50-day moving average price is $4.68 and its two-hundred day moving average price is $5.63. Evolus has a 1 year low of $3.86 and a 1 year high of $12.28. The company has a market capitalization of $346.77 million, a price-to-earnings ratio of -6.58 and a beta of 1.28.

Insider Activity

In related news, insider David Moatazedi sold 116,720 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total transaction of $570,760.80. Following the sale, the insider owned 618,369 shares in the company, valued at approximately $3,023,824.41. This represents a 15.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Rui Avelar sold 29,996 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total value of $146,680.44. Following the transaction, the insider directly owned 430,542 shares of the company’s stock, valued at $2,105,350.38. This trade represents a 6.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 163,504 shares of company stock valued at $797,184 in the last 90 days. 5.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Evolus

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Evolus by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock valued at $400,000 after buying an additional 1,838 shares during the last quarter. Millennium Management LLC increased its holdings in Evolus by 1.7% during the first quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock worth $16,746,000 after buying an additional 23,605 shares during the last quarter. Jones Financial Companies Lllp acquired a new position in Evolus during the first quarter worth $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Evolus by 36.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company’s stock worth $1,883,000 after acquiring an additional 41,513 shares in the last quarter. Finally, Jane Street Group LLC raised its position in Evolus by 484.8% during the first quarter. Jane Street Group LLC now owns 69,947 shares of the company’s stock worth $841,000 after acquiring an additional 57,987 shares in the last quarter. Institutional investors own 90.69% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on EOLS. Mizuho set a $15.00 price objective on Evolus in a report on Wednesday, February 4th. Wall Street Zen cut Evolus from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th. Stifel Nicolaus reduced their price target on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, January 13th. BTIG Research reaffirmed a “buy” rating and set a $13.00 price target on shares of Evolus in a research note on Wednesday, March 4th. Finally, Weiss Ratings downgraded shares of Evolus from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Evolus presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.